Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BioCorRx Inc. (BICX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
5.00000.0000 (0.00%)
At close: 03:55PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.0000
Open5.0000
BidN/A x N/A
AskN/A x N/A
Day's Range4.7000 - 5.0000
52 Week Range0.1550 - 8.1000
Volume1,191
Avg. Volume2,244
Market Cap33.092M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-0.7190
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.65
  • GlobeNewswire

    BioCorRx to Participate in the Benzinga All Access Event on December 2nd

    ANAHEIM, CA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO and Director of BioCorRx, Inc. and Brady Granier, President and Director, CEO of BioCorRx Pharmaceuticals, will be participating in the Benzinga All Access event taking place on December 2, 2021. Ms. Felix and Mr. Granier are scheduled to pre

  • GlobeNewswire

    BioCorRx Acquires Intellectual Property for Drug Delivery

    Patent Application Covers Solid Implant Formulation for Drug Delivery ANAHEIM, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the Company has acquired a patent application from Calista Therapeutics. The current application, 17/465,748, was filed with the U.S. Patent and Trademark Office (USPTO) covering solid implant form

  • GlobeNewswire

    BioCorRx Provides Business Update for the Third Quarter of 2021

    ANAHEIM, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September 30, 2021 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., stated, “We are pleased to report continued meaningful progress towards U.S. Food and Drug Administration

Advertisement
Advertisement